MTS assays indicated similar loss in cell viability in KLF9-expressing GSCs when treated with SAHA or TSA (Fig. 2a, b), suggesting a universal tumor cell killing effect of KLF9 in conjunction with HDAC inhibitors. The gene discussed is KLF9; the disease is neoplasm.